Find clinical trials

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

The purpose of this study is to test multiple doses of the study drug to see how CB03- 154 works, when compared to placebo, in controlling focal seizure frequency in adults with focal epilepsy who are already taking 1 to 3 antiepileptic drugs (AEDs), and to assess the safety and tolerability of CB03-154 in adults with focal epilepsy. In addition, this study will help determine how the study drug is processed by the body and will measure the effect of the study drug compared to placebo and in addition to standard of care treatment. The study involves approximately 168 patients who will be divided into four groups in a blinded and randomized manner. Each group will receive either one of three different doses of the investigational drug CB03-154 (20 mg, 10 mg, or 5 mg) or a placebo. The assignment to these groups will be completely random and both participant and the study team will not know which treatment they are receiving. The duration of the study is approximately 22 weeks: screening/Baseline least 8 weeks, double-blind treatment period of 12 weeks, and post-treatment follow-up period of 2 weeks (+7 days) after last dose.

This is a Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed with Epilepsy. This study is an extension of a previous study called CB03-154-EP201. It aims to evaluate the long-term safety, tolerability, effectiveness and how the body processes the medication (known as pharmacokinetics or PK) of CB03-154 (known as the study drug) in the treatment of adult patients with epilepsy. Participants who successfully completed and did not terminate study treatment early from the CB03-154-EP201 study will be eligible for this study. This study has a treatment period of 104 weeks, and a down-titration (study drug dosage will be gradually reduced)/follow-up period of 8 weeks. The treatment duration will be up to 2 years. A data safety monitoring board (DSMB) will be established by the sponsor to review cumulative safety data at regular intervals throughout the study and monitor overall study conduct.

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. Part 1 has been complete. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: Can combining tebentafusp with IL-2 improve tumor response and overall survival? What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1 Day1-3 IL-2, Day4 Tebentafusp, Day 10 IL-2, Day 11 Tebentafusp, Day 17 IL-2, Day 18 Tebentafusp, Day 24 IL-2, Day 25 Tebentafusp. Cycle 2 & thereafter: Day 1 IL-2, Day 2 Tebentafusp, Day 8 IL-2, Day 9 Tebentafusp, Day 15 IL-2, Day 16 Tebentafusp, Day 22 IL-2, Day 23 Tebentafusp.

This study aims to investigate immune reactions that can be involved in atopic dermatitis (eczema). It will do this by examining the composition and differences in the microorganisms, gene expression (regulated processes that allow a cell to respond to its changing environment) and lipids/metabolites (small proteins, sugars or fats produced by cells) of people with eczema vs. people without. This will potentially support more personalised and effective treatments for people with eczema and ultimately improve patient care.